Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WelChol in Type 2 Diabetes on Insulin Therapy
NCT00151749Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2004
- Primary completion
- Dec 2005
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing WelChol with Placebo (2 arms). Primary endpoint: Hemoglobin A1c at 26 weeks. Started Jun 2004; status: completed.
02
Drugs
colesevelam
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00151749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151749.